Arcus Biosciences (RCUS) announced the first OS results from Arm A1 of the Phase 2 EDGE-Gastric study in patients with locally advanced unresectable or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma. The ongoing, multi-arm, global Phase 2 EDGE-Gastric study is evaluating the safety and efficacy of various combinations of the Fc-silent anti-TIGIT antibody domvanalimab plus the anti-PD-1 monoclonal antibody zimberelimab and chemotherapy in this patient population. This study was conducted in partnership with Gilead Sciences. These results will be presented in a mini oral session at the ESMO 2025 Congress. In addition to describing OS data, this presentation also includes updated progression-free survival, PFS, and objective response rate, ORR, data, which are consistent with prior reports on this study. At data cutoff, safety and efficacy were evaluated in all patients enrolled and treated, and median study follow-up was 26.4 months. Efficacy was observed across all PD-L1 subgroups. With a median time on treatment of 49 weeks, the domvanalimab plus zimberelimab and chemotherapy regimen demonstrated sustained efficacy with longer follow-up.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCUS:
- Arcus Biosciences price target raised to $39 from $32 at Truist
- Arcus Biosciences’ Casdatifan Shows Superior Efficacy and Safety in ccRCC Treatment, Supporting Buy Rating
- Arcus Biosciences: Promising Efficacy and Manageable Safety Profile Drive Buy Rating
- Truist says Arcus Biosciences data for Casdatifan ‘looks like a home run’
- Arcus Biosciences Presents Promising ARC-20 Study Data